Spike Protein News and Research

RSS

Evidence of an increased risk of neurodegeneration after SARS-CoV-2 infection

...

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

Scientists have discovered a new generation of angiotensin receptor blockers that may be used to treat coronavirus disease 2019.

11 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

The effect of unsuppressed HIV on T-cell response to COVID-19

A new study evaluates the impact of HIV infection on SARS-CoV-2 T-cell responses during the first and second waves of COVID-19 in South Africa.

10 Apr 2022

Computational network science approach reveals new mechanisms for coronaviruses infections

A group of bat viruses related to SARS-CoV-2 can also infect human cells but uses a different and unknown entryway.

8 Apr 2022

UGA researchers develop nanotechnology-based optical sensors for rapid coronavirus detection

A University of Georgia nanotechnology research group entered the race to develop a rapid test for COVID-19 in August 2020, running experiments on a new sensor for an American manufacturing company.

7 Apr 2022

Study suggests blunted serological responses not responsible for COVID-19 mortality

A new study investigated serological profiling to determine the antibody responses in critically ill COVID-19 positive and negative patients.

7 Apr 2022

COVID boosters protect you better than monoclonal antibodies, or natural infection

In a new study published in the journal Science Translational Medicine, researchers analyzed the neutralization of the Omicron BA.1 variant pseudovirus by post-vaccination serum samples.

6 Apr 2022

Self-assembling SARS-CoV-2 spike protein-directed nanoparticle vaccines

A new preprint study depicted the generation of self-assembling coronavirus disease 2019 (COVID-19) nanoparticle vaccines.

6 Apr 2022

Study evaluates the presence of the SARS-CoV-2 spike protein in urine samples collected during the COVID-19 pandemic

A study published analyzed the presence of SARS-CoV-2 spike protein in urine samples of the infected patients.

6 Apr 2022

Developing and manufacturing custom recombinant antibodies for R&D

In this interview, Dr. Linlin Zhang, technical specialist for Sino Biological Europe, discusses how Sino is expanding its product offerings into the European market and outlines its process for developing and manufacturing custom recombinant antibodies for their clients.

From Sino Biological Inc. 6 Apr 2022